# Health and Care Act 2022, Paragraph 138: National Health Service Act 2006

Extent: E+W

In Schedule 12A (pharmaceutical remuneration), in paragraph 2—
(a) in the heading for “clinical commissioning groups” substitute “integrated care boards”;
(b) in sub-paragraph (3), for “clinical commissioning group” substitute “integrated care board”;
(c) in sub-paragraph (4), for “clinical commissioning groups” substitute “integrated care boards”;
(d) in sub-paragraph (5), for “clinical commissioning group” substitute “integrated care board”;
(e) in sub-paragraph (6)—
(i) for “a clinical commissioning group” substitute “an integrated care board”;
(ii) in paragraphs (a) and (b), for “the group”, in both places it occurs, substitute “the board”;
(f) in sub-paragraph (8), for “a clinical commissioning group” substitute “an integrated care board”;
(g) for sub-paragraph (9) substitute—
“(9) For the purposes of sections 223GC and 223M(1)(b) and paragraph 22 of Schedule 1B, any amount of which an integrated care board is notified under sub-paragraph (6) is to be treated as expenditure of the group which is attributable to the performance by it of its functions in the year in question.”

---
Source: https://www.legislation.gov.uk/ukpga/2022/31/schedule/4/paragraph/138 (the official version)
Page: https://openlegislation.uk/health-and-care-act-2022/schedule-4/paragraph-138
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.